OCTREO
hynic-octreotide
Image for illustration purposes only.
Presentation: Kit containing 2 sterile and non-pyrogenic vials for complexation with the radioisotope metastable technetium-99m (99mTc) comprising 1 vial of lyophilized powder for injectable solution and 1 vial of injectable solution.
Indication: diagnosis and management of somatostatin receptor bearing neuroendocrine tumours (NET), by aiding their localization.
Storage: 2-8°C
Labeling volume: 1-2 mL
Labeling activity: 30 mCi
Stability post-labeling: 4 hours in room temperature (15 to 30 ºC).
Product expiration date: 12 months
Number of vials per kit: 2
Contraindications, warnings, precautions and posology: refer to package leaflet.
Commercialization supported by RESOLUTION – RDC No. 738/2022, dated July 28, 2022.
AVAILABLE BY PRESCRIPTION ONLY – RESTRICTED USE TO HOSPITALS.
IF SYMPTOMS PERSIST, A DOCTOR SHOULD BE CONSULTED.
Contraindications, warnings, adverse reactions, drug interactions, precautions and posology: refer to package leaflet.
R2Pharma products are available only by means of medical prescription from a licensed physician.
IF SYMPTOMS PERSIST, A DOCTOR SHOULD BE CONSULTED.
Contraindications, warnings, adverse reactions, drug interactions, precautions and posology: refer to package leaflet.
The content of this page is destined to health professionals.